Healthcare, Pharma & Life Sciences

Linköping – November 04, 2026 -- Sectra (STO: SECT B) has signed a seven-year contract with Mount Sinai Health System in New York to deliver Sectra Reporting across all radiology services, covering more than 1.2 million exams per year.

Mount Sinai becomes the first US health system to adopt Sectra for radiology reporting

Sectra Reporting is the native reporting module in Sectra One Cloud, the company's enterprise imaging solution. The contract was signed in the second quarter of Sectra's 2026/2027 fiscal year. Go-live is planned for spring 2027.

Mount Sinai already uses Sectra's enterprise imaging solution for radiology, breast imaging and enterprise archive. Sectra says adding reporting to the same platform reduces vendor complexity and simplifies IT management.

Incheon – November 03, 2026 -- Samsung Biologics (KRX: 207940.KS) has earned an ESG Risk Rating score of 9.0 from Morningstar Sustainalytics, placing the contract development and manufacturing organization (CDMO) among the top 0.5% of companies assessed in the pharmaceuticals industry.

Samsung Biologics moves from 'Low Risk' to the lowest of five risk categories

The company advanced to 'Negligible Risk' from its previous 'Low Risk' rating. Under Sustainalytics' methodology, scores below 10 indicate a negligible level of unmanaged ESG risk, and lower scores reflect lower overall risk.

Morningstar Sustainalytics, an independent ESG research and ratings provider, assesses approximately 16,000 companies worldwide. It measures their exposure to material ESG risks and how effectively those risks are managed.

RIDGEWOOD – – November 03, 2026 -- SportsMed Physical Therapy has opened its Jersey City Heights clinic, lifting its network to 58 locations across New Jersey and Connecticut.

Hudson County presence expands with the new site

The Jersey City Heights clinic adds capacity in Hudson County, where the company now serves more residents, families and athletes recovering from injuries, managing pain or improving mobility.

The site offers physical therapy, occupational and hand therapy, chiropractic care, acupuncture and HomeCare services.

Network has grown from 7 to 58 sites since 2018

SportsMed has expanded from 7 to 58 locations since partnering with Hildred Capital Management in 2018. Hildred is a New York City-based investor in lower middle-market healthcare companies, and SportsMed is one of its portfolio companies.

Holland and Knight acted as legal counsel to SportsMed on the opening.

SUZHOU – November 03, 2026 -- CStone Pharmaceuticals (HKEX: 2616) will lead Phase I development of Kimia Therapeutics' potential first-in-class DNA damage response (DDR) cancer drug in mainland China and Australia, while Kimia reimburses the applicable clinical development costs.

CStone gains milestone and royalty rights without funding the trials

Under the clinical collaboration agreement, CStone is eligible for milestone payments and royalties on global net sales of the asset during the applicable royalty term. Kimia will supply the clinical drug, scientific guidance and product-related regulatory oversight. The announcement did not disclose payment amounts or royalty rates.

The asset targets the DDR pathway, which solid tumor cells rely on to survive.

Arlington, Virginia – November 03, 2026 -- The President has signed the bipartisan ACT for ALS Act into law, extending the research and treatment access programs created under the original 2021 legislation through 2031, according to the ALS Association.

Reauthorization keeps 2021 research and access programs running to 2031

The measure continues the programs established when ACT for ALS first passed in 2021. The ALS Association says those programs have accelerated research into promising therapies. The reauthorization is built to help the field establish which treatments work and to deliver them to everyone living with ALS.

SEATTLE – November 03, 2026 -- Pioneer Human Services reported an 8% recidivism rate and a 74% successful diversion rate in its Q3 2026 Impact Report. Both outcomes were measured after at least one year of service. The recidivism figure comes from a representative sample of clients.

Tuition assistance feeds Pioneer's treatment and reentry teams

Since 2024, 87% of Pioneer employees who received tuition assistance work in the organization's treatment and reentry services division. The education assistance program supports staff pursuing additional credentials and degrees, which the nonprofit says opens career advancement paths and adds capacity to meet rising demand for behavioral health services.

Pioneer is investing in existing staff because Washington faces a shortage of behavioral health professionals.

Santa Clara – November 03, 2026 -- LeanTaaS has acquired LookDeep Health and launched iQueue for Virtual Care, citing deployment results of more than 70% lower fall rates and an 80% reduction in medication errors from the acquired vision AI technology.

The launch is the first product under LeanTaaS' plan to build ambient intelligence into its iQueue capacity management, staffing and patient flow platform. The company introduced it at the Transform Executive Summit, held alongside Becker's CEO + CFO Roundtable.

Copenhagen – November 03, 2026 -- Cambiotics ApS has enrolled the first participant in its first human clinical trial, testing whether its probiotic strain 46-SL1 changes serum PFAS concentrations in 70 firefighters with prior occupational exposure.

Crossover trial runs 2 x 12 weeks in Chicago

The study is randomised, double-blind and placebo-controlled. Atlantia Clinical Trials is conducting it in Chicago, Illinois (NCT07846371). Researchers are also assessing safety, tolerability and fecal microbiome changes. 46-SL1 is being developed as a dietary supplement.

Dr. Stacey Boetto of Atlantia Clinical Trials is the Principal Investigator.

MUMBAI – – November 03, 2026 -- Lupin Limited has launched Raltegravir Tablets USP, 600 mg in the United States and is eligible for 180-day generic drug exclusivity, after the U.S. FDA approved its Abbreviated New Drug Application.

The product is bioequivalent to the reference listed drug Isentress HD Tablets, 600 mg, marketed by Merck Sharp & Dohme, LLC. Lupin is the exclusive first-to-file applicant for the product.

Reference product generated an estimated USD 26 million in annual US sales

Isentress HD 600 mg had estimated annual U.S. sales of USD 26 million, according to IQVIA MAT September 2026 data. That figure is the market the 180-day exclusivity window covers for Lupin.

SMITHFIELD, R.I. – November 03, 2026 -- Acclaro Medical will showcase UltraClear, which it describes as the world's first 2910 nm cold ablative fiber laser, at the American Society for Dermatologic Surgery (ASDS) Annual Meeting, held November 4-8 in San Diego, California.

The company is using the conference to promote UltraClear as the anchor of a new skin resurfacing category. The platform covers treatments from prejuvenation and superficial resurfacing to advanced procedures, including treatment of excess skin with the proprietary Laser-Coring technique. Acclaro says the fiber laser is designed for all skin types, with faster healing and greater patient comfort.

Acclaro pitches the system as a single adaptable platform. Physicians can adjust treatments by skin concern, skin type, treatment depth and aesthetic objective. Indications cited include skin aging, pigmentation, scars and the effects of gravity.